Celltrion Pharm, Inc. (068760.KQ)
KRW 48600.0
(0.41%)
KRW 48600.0
(0.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 142.81 Billion KRW | 10.45% |
| 2022 | 129.3 Billion KRW | 28.22% |
| 2021 | 100.84 Billion KRW | -39.71% |
| 2020 | 167.27 Billion KRW | 10.69% |
| 2019 | 151.12 Billion KRW | 9.62% |
| 2018 | 137.85 Billion KRW | -0.54% |
| 2017 | 138.61 Billion KRW | 7.84% |
| 2016 | 128.53 Billion KRW | -37.93% |
| 2015 | 207.08 Billion KRW | 125337.28% |
| 2014 | 165.08 Million KRW | -4.75% |
| 2013 | 173.31 Million KRW | 3257.51% |
| 2012 | -5.48 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 153.99 Billion KRW | 20.39% |
| 2024 Q1 | 127.91 Billion KRW | -10.44% |
| 2023 Q4 | 142.81 Billion KRW | -14.98% |
| 2023 Q1 | 124.7 Billion KRW | -3.56% |
| 2023 Q2 | 138.66 Billion KRW | 11.19% |
| 2023 FY | 142.81 Billion KRW | 10.45% |
| 2023 Q3 | 167.97 Billion KRW | 21.14% |
| 2022 FY | 129.3 Billion KRW | 28.22% |
| 2022 Q3 | 145.01 Billion KRW | 0.67% |
| 2022 Q2 | 144.05 Billion KRW | 14.92% |
| 2022 Q1 | 125.34 Billion KRW | 24.29% |
| 2022 Q4 | 129.3 Billion KRW | -10.83% |
| 2021 Q3 | 123.49 Billion KRW | -16.52% |
| 2021 Q1 | 166.12 Billion KRW | 99462.36% |
| 2021 FY | 100.84 Billion KRW | -39.71% |
| 2021 Q4 | 100.84 Billion KRW | -18.34% |
| 2021 Q2 | 147.93 Billion KRW | -10.95% |
| 2020 FY | 167.27 Billion KRW | 10.69% |
| 2020 Q1 | 145.91 Million KRW | -3.21% |
| 2020 Q2 | 157.34 Million KRW | 7.83% |
| 2020 Q3 | 177.66 Million KRW | 12.92% |
| 2020 Q4 | 166.85 Million KRW | -6.09% |
| 2019 Q3 | 152.12 Million KRW | -0.13% |
| 2019 Q2 | 152.32 Million KRW | 7.0% |
| 2019 FY | 151.12 Billion KRW | 9.62% |
| 2019 Q1 | 142.36 Million KRW | 3.26% |
| 2019 Q4 | 150.75 Million KRW | -0.9% |
| 2018 Q2 | 144.21 Million KRW | 5.3% |
| 2018 Q1 | 136.95 Million KRW | -1.19% |
| 2018 FY | 137.85 Billion KRW | -0.54% |
| 2018 Q4 | 137.85 Million KRW | -9.95% |
| 2018 Q3 | 153.08 Million KRW | 6.15% |
| 2017 FY | 138.61 Billion KRW | 7.84% |
| 2017 Q1 | 132.66 Million KRW | 3.21% |
| 2017 Q3 | 136.82 Million KRW | 1.04% |
| 2017 Q2 | 135.41 Million KRW | 2.07% |
| 2017 Q4 | 138.61 Million KRW | 1.31% |
| 2016 FY | 128.53 Billion KRW | -37.93% |
| 2016 Q2 | 155.08 Million KRW | -14.66% |
| 2016 Q1 | 181.72 Million KRW | -11.87% |
| 2016 Q3 | 162.68 Million KRW | 4.9% |
| 2016 Q4 | 128.53 Million KRW | -20.99% |
| 2015 Q4 | 206.21 Million KRW | 6.65% |
| 2015 FY | 207.08 Billion KRW | 125337.28% |
| 2015 Q1 | 179.38 Million KRW | 8.66% |
| 2015 Q3 | 193.34 Million KRW | 0.98% |
| 2015 Q2 | 191.46 Million KRW | 6.74% |
| 2014 Q1 | 183.06 Million KRW | 5.62% |
| 2014 Q2 | 189.82 Million KRW | 3.69% |
| 2014 Q3 | 197.57 Million KRW | 4.08% |
| 2014 Q4 | 165.08 Million KRW | -16.44% |
| 2014 FY | 165.08 Million KRW | -4.75% |
| 2013 Q3 | 134.54 Million KRW | 12.06% |
| 2013 Q1 | -2.76 Million KRW | 49.66% |
| 2013 Q2 | 120.06 Million KRW | 4445.51% |
| 2013 Q4 | 173.31 Million KRW | 28.81% |
| 2013 FY | 173.31 Million KRW | 3257.51% |
| 2012 Q4 | -5.48 Million KRW | 0.0% |
| 2012 FY | -5.48 Million KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | -653.2% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | -660.299% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | -976.644% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | -223.155% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | 1555.337% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 284.17% |
| Boditech Med Inc. | -31.92 Billion KRW | 547.33% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | -2825.658% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | 2996.509% |
| Huons Co., Ltd. | 73.9 Billion KRW | -93.23% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 311.108% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | 1282.029% |